secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2026-06-16T12:10:17+00:00
Accession:  0001493152-26-028815
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate receives first US patent for ADHD drug CTx-1301 through Dec 2042
--------------------------------------------------------------------------

- USPTO issued Patent No. 12,653,791 covering CTx-1301 formulation and method of use through Dec 2042.
- First company-owned US patent for lead ADHD asset; includes composition-of-matter and method-of-treatment claims.
- Cingulate holds additional patents in 30 European territories, Australia, Canada, Israel; applications pending in Hong Kong and South Korea.
- CTx-1301 is a once-daily trimodal tablet using Precision Timed Release platform; being developed under FDA 505(b)(2) pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315226028815/0001493152-26-028815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315226028815/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-028815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer